Investing in Athletes is Legal Now and Barely Anyone Does

On May 22, 2026, a San Diego judge closed the book on the most famous bet ever placed on an athlete’s future. Fernando Tatis Jr. had signed a contract at 17, before he’d played a single major league game: $2 million up front from an investment fund called Big League Advance, in exchange for 10% of whatever he went on to earn in baseball. Four years later he signed a $340 million extension with the Padres. He sued to void the deal, arguing it was a predatory loan dressed up as an investment.

He lost. The court ordered him to pay Big League Advance roughly $3.74 million, a figure that includes an arbitration award of about $3.23 million plus interest, attorney’s fees and costs, according to ESPN’s reporting on the case.

That lawsuit is the origin story for an entire retail financial product. If a fund could turn $2 million into a claim on a $340 million contract, the thinking went, why should only funds get to play? By 2026 they don’t have to. A handful of SEC-registered platforms now sell the same structure to ordinary people in $100 slices.

Investing in an athlete’s future earnings means buying a security that entitles the holder to a fixed percentage of one specific athlete’s on-field income for a set number of years, sold through SEC-qualified platforms including Agentiq, Finlete and FANtium.

The filings behind those platforms tell a story nobody is putting in the marketing: the product works more or less exactly as advertised, and almost nobody is buying it.

Last updated: September 2026

Quick answers

How does investing in an athlete’s future earnings work?

A platform signs a player agreement paying an athlete cash up front in exchange for a percentage of that athlete’s pre-tax future on-field earnings. The platform then sells shares tied to that percentage to investors. When the athlete gets paid, the platform collects its cut and distributes most of it to shareholders.

Is it legal to buy a share of an athlete’s future earnings?

Yes, when it’s structured as a registered security. Agentiq uses Regulation A Tier 2, Finlete has used Regulation Crowdfunding, and both file offering documents with the SEC. The unsettled legal question isn’t securities law but state consumer-lending law, which the Tatis case put directly in play.

What is Agentiq?

Agentiq is a San Francisco company that securitizes professional athletes’ future on-field earnings and sells the resulting shares to fans and retail investors. Its first athlete is Washington Nationals infield prospect Ronny Cruz, whose deal was filed with the SEC in June 2026.

How investing in an athlete’s future earnings works

Every deal in this category runs on the same two-step structure: a private contract between the platform and the athlete, then a public offering of shares tied to that contract. The athlete never sells shares directly. The platform is always in the middle, and that middle position is where most of the investor risk actually lives.

Step one is the player agreement. Agentiq agreed to pay Ronny Cruz up to $1.2 million, plus branding support, for up to 10% of his future on-field earnings in both the minors and the majors, as Sportico reported. Cruz, an infielder with the High-A Wilmington Blue Rocks, also granted royalty-free use of his name, image and likeness for promotion, and agreed to repay the investment with interest if he retires within five years for any reason other than illness or injury.

Step two is the offering. Agentiq is selling 12,900 shares at $100 each, a $1.29 million raise, through a Regulation A Tier 2 filing made in June 2026. Buy one share and you own a claim on roughly one twelve-thousand-nine-hundredth of whatever percentage the platform ends up holding.

Finlete’s SEC filings spell the arithmetic out more precisely than any platform’s marketing page does. In its first completed Regulation CF offering, closed on August 7, 2024, Finlete Funding raised $78,288, issued 9,786 shares of Echedry Vargas Preferred Stock, and received a 1% interest in Vargas’s pre-tax future professional baseball earnings. Per the company’s offering statement, every single share entitles its holder to 0.000009% of Vargas’s pre-tax future earnings, and holders receive 90% of the player payments the company collects, net of what it owes back under the player agreement.

The term is the part people skim past. The Vargas agreement runs 25 years from its effective date. You are not buying a trade. You’re buying a quarter-century claim on someone’s paychecks, with no secondary market to exit into.

Is investing in athletes’ future earnings legal?

Yes, and the legal question that matters isn’t the one most people ask. Buying a share of an athlete’s future earnings is legal in the United States when the interest is structured and sold as a registered or exempt security, which is why Agentiq filed under Regulation A Tier 2 and Finlete has used Regulation Crowdfunding. The SEC has qualified offerings in this category since at least 2024.

Regulation A Tier 2 is the workhorse here. It allows raises up to $75 million a year without the full reporting burden of a public company, which is why a $1.29 million athlete offering can exist at all. Regulation CF, which Finlete used for Vargas, caps out much lower and carries a one-year lockup before shares can be resold.

The unsettled exposure is state consumer-lending law. Tatis didn’t argue that Big League Advance sold an unregistered security. He argued the deal was an illegal loan, that Big League Advance hid its unlicensed status, and that the terms violated California consumer protection rules. He lost that argument in his specific case, but the theory itself survived contact with a courtroom, and law firms noticed. Venable’s post-Tatis guidance for structuring athlete financing deals flags lending, licensing, usury and disclosure requirements as jurisdiction-by-jurisdiction problems that sit alongside securities compliance rather than being solved by it.

For an investor, that translates into a specific question worth asking before wiring money: if a state regulator later recharacterizes these agreements as consumer loans, what happens to the platform holding your 25-year claim? No offering document currently answers that cleanly.

Which platforms let you invest in athletes in 2026

Four platforms dominate the category in 2026, and they are not selling the same thing. Agentiq, Finlete and FANtium sell claims on individual athletes’ earnings. PlayersTV sells equity in a media company that athletes co-own, which is a completely different asset wearing similar marketing.

FANtium is the structural outlier among the earnings-share platforms. It runs on Polygon, pays out in USDC, and gates payouts behind a performance trigger: token holders participate in an athlete’s prize money and endorsement income once that player breaks into the ATP or WTA top 150, for up to ten seasons. If the player never cracks the top 150, the trigger never fires.

PlayersTV belongs in the comparison mostly so buyers stop confusing it with the others. It raised $3.2 million from about 2,200 fan investors at a $75 million pre-money valuation, with athlete partners including Chris Paul, Travis Kelce and Dwyane Wade, as Forbes covered. Buying in makes you a shareholder in a media business. It does not give you a claim on Travis Kelce’s contract.

What you’re actually buying, and what you’re not

An athlete earnings share is a fractional, illiquid, single-name credit bet with no collateral and a 25-year duration. That’s the honest description, and it’s worth holding next to the marketing, which tends to describe the same instrument as backing a player you believe in.

Three things you are not buying. You are not buying equity in the athlete, because there’s no such thing. You are not buying a tradeable asset, because these platforms have no functioning secondary market. And you are not buying a claim on total career income, because the agreements cover on-field earnings specifically, which excludes the endorsement money that makes most famous athletes rich.

That last exclusion does more damage than it looks. Under the Agentiq structure, the platform takes on-field earnings and separately gets royalty-free promotional use of Cruz’s name and likeness. If Cruz becomes a star, the endorsement upside that follows sits outside what shareholders bought.

The distribution waterfall matters too. Finlete’s Vargas shareholders are entitled to 90% of the player payments the company receives, less amounts owed back under the player agreement. Read that in order: the athlete pays the platform, the platform settles its own obligations, then investors get most of what’s left. You sit at the bottom.

Why almost nobody is actually buying

The most useful number in this category isn’t a return figure. It’s the gap between what these offerings were cleared to sell and what they actually sold, and that gap is enormous at every level of the market.

Start with Finlete’s own filing. The Vargas offering issued 9,786 shares against 100,000 authorized, leaving 90,214 unissued. The company raised $78,288 on a product that was set up to raise roughly ten times that. The follow-on tells the same story from a different angle: Finlete signed a player agreement with Emmanuel Clase contemplating payments of up to $2.5 million, and the offering ultimately delivered a 0.125% interest in his pre-tax future earnings. That is a fraction of the stake the agreement was built to support.

Across its whole book, Finlete had transacted roughly $1 million from about 1,000 investors across a dozen minor league players as of early 2026. Spread across twelve athletes, that’s an average of about $83,000 per player. And the audited financials carry a going-concern note from the company’s auditor, which is a formal statement that the platform’s own survival is in question.

The professional money isn’t any more convinced. Big League Advance’s third fund targeted $250 million and held $41.6 million in assets as of March 2024, per Sportico’s reporting on why athlete futures have been a hard sell. This is the firm with the Tatis win in its track record, the single best marketing asset the category has ever produced, and it still came in at 17% of target.

Two flywheels are failing at once. Retail buyers don’t have a liquid, understandable product to hold. Institutions can’t underwrite enough players to make outcomes predictable. The result is a category with real SEC filings, real athletes, real capital flowing to prospects who need it, and almost no investor demand on the other side.

Is investing in athletes a good investment?

For most people, no, and the reason has more to do with structure than with athlete performance. An athlete earnings share concentrates single-name risk, offers no exit before payout, runs for up to 25 years, and sits behind the platform’s own solvency. Any one of those would be disqualifying in a conventional portfolio. Together they describe a lottery ticket with a quarter-century expiry.

The athlete risk is real but secondary. Most minor league players never reach the majors, and the ones who do rarely arrive on the schedule an investor is modeling. Cruz is in High-A. Under his agreement, if he retires within five years for any reason other than illness or injury, he owes the investment back with interest, which protects the platform, not you.

The platform risk deserves more attention than it gets. A going-concern note in an audited financial statement means the auditor sees substantial doubt about whether the business continues. If the platform folds, the mechanism that collects payments from the athlete and routes them to shareholders folds with it. Your claim would then depend on whatever the wind-down produces.

There’s a narrower case where this makes sense. If you’d buy the share for the same reason you’d buy a jersey, and the amount is money you’d be fine setting on fire, the emotional return is real and the financial downside is capped at what you spent. Treat it as fandom with an upside option, not as an allocation. If you’re weighing it against other alternatives, our breakdown of key investment opportunities and risks for the 2026 market covers the conventional side of the ledger.

What founders should take from the athlete stock market

The athlete earnings category is a case study in building a legally sound product for a market that doesn’t exist yet. Agentiq, Finlete and FANtium solved the hard technical problem, which was structuring an entirely new asset class so the SEC would qualify it. Then they hit the problem nobody funds: nobody wanted to buy it.

The regulatory work these teams did is genuinely difficult. Securitizing one person’s future labor income, filing a Form 1-A that clears SEC review, and building the payment plumbing to route earnings to thousands of small shareholders is years of legal and engineering work. It’s also, on the evidence, the easy half.

The instructive failure is distribution. Finlete’s roughly 1,000 investors after multiple offerings is a customer acquisition number, not an investing outcome. The bet was that fandom would substitute for financial rationale, that people who buy jerseys would buy shares. Fans buy jerseys because jerseys cost $120 and require no thesis. A 25-year illiquid security requires one.

There’s a cleaner version of this trade that founders should notice, because the capital in this space is flowing in the opposite direction. Athletes pooling their own money into funds and cap tables have raised far more, far faster, than platforms selling slices of athletes to fans. The CHAMP Fund’s athlete co-ownership model put more than $50 million of athletes’ own capital into a $500 million consumer brand fund, and athletes who move from endorsements into ownership stakes like Breanna Stewart’s are compounding equity rather than selling their future paychecks. The pattern that’s working has athletes on the buy side.

If you’re building in a category with no established buyer, the athlete stock market is the warning label. Validate that someone wants the instrument before you spend two years making it legal. Founders looking at adjacent plays can start with how athletes have turned into operators and entrepreneurs, or with the broader shift toward income-diversifying business models that don’t require inventing a securities structure first. For the fundamentals of building revenue without a new asset class, our guide to making money online and offline is a more grounded starting point, and our finance coverage tracks where this category goes next.

Investing in athletes’ future earnings is now a legal, functioning, SEC-qualified product. It’s just one almost nobody has agreed to buy.